Structure Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Structure Therapeutics Inc. (GPCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $24.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-02-26
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-12-31 was $5.30M, a 165.00% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-09-30 was $5.20M, a 205.88% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-06-30 was $3.50M, a 600.00% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-03-31 was $5.80M, a 346.15% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $24.90M, a 25.76% increase from fiscal 2024.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $19.80M, a 260.00% increase from fiscal 2023.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $5.50M, a 266.67% increase from fiscal 2022.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $1.50M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $24.90M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.50M derived: sum of 2 quarters · filed 2026-02-26 | $14.00M derived: sum of 3 quarters · filed 2026-02-26 | $19.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.20M 10-Q · filed 2024-11-13 | $8.70M derived: sum of 2 quarters · filed 2024-11-13 | $14.50M 10-Q · filed 2024-11-13 | $16.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.50M 10-Q · filed 2024-08-08 | $9.30M 10-Q · filed 2024-08-08 | $11.30M derived: sum of 3 quarters · filed 2026-02-26 | $13.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.80M 10-Q · filed 2024-05-09 | $7.80M derived: sum of 2 quarters · filed 2026-02-26 | $9.50M derived: sum of 3 quarters · filed 2026-02-26 | $10.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.70M derived: sum of 2 quarters · filed 2026-02-26 | $4.20M derived: sum of 3 quarters · filed 2026-02-26 | $5.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.70M 10-Q · filed 2024-11-13 | $2.20M derived: sum of 2 quarters · filed 2024-11-13 | $3.50M 10-Q · filed 2024-11-13 | $3.90M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-08 | $1.70M 10-Q · filed 2024-08-08 | $2.20M derived: sum of 3 quarters · filed 2024-08-08 | $2.60M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-09 | $1.70M derived: sum of 2 quarters · filed 2024-05-09 | $2.10M derived: sum of 3 quarters · filed 2024-05-09 | $2.70M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $800.00K derived: sum of 2 quarters · filed 2024-03-08 | $1.40M derived: sum of 3 quarters · filed 2024-03-08 | $1.50M 10-K · filed 2024-03-08 |
| 2022-09-30 | $400.00K 10-Q · filed 2023-11-17 | $1.00M derived: sum of 2 quarters · filed 2023-11-17 | $1.10M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $600.00K 10-Q/A · filed 2023-11-17 | $700.00K 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |